The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
What is principal component analysis?
Ringnér, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0308-303 · Cited by 2,407
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Tankyrase, a Poly(ADP-Ribose) Polymerase at Human Telomeres
Smith, S., Giriat, I., Schmitt, A., & de Lange, T. (1998) · Science · doi:10.1126/science.282.5393.1484 · Cited by 1,012
Cited by
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
HemI: A Toolkit for Illustrating Heatmaps
Deng, W., Wang, Y., Liu, Z., Cheng, H., & Xue, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111988 · Cited by 991
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
“Molecular strategies for targeting PARPs The majority of currently available PARPis has a relatively broad spectrum across the PARP family (Wahlberg et al. 2012).”
BackgroundInfluentialPARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Family-wide analysis of poly(ADP-ribose) polymerase activity
Vyas, S., Matic, I., Uchima, L., Rood, J., Zaja, R., Hay, R. T., Ahel, I., & Chang, P. (2014) · Nature Communications · doi:10.1038/ncomms5426 · Cited by 497
Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins
Alemasova, E. E., & Lavrik, O. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz120 · Cited by 497
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200043 · Cited by 426
Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
Self-citationPoly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome
Zhang, Y., Wang, J., Ding, M., & Yu, Y. (2013) · Nature Methods · doi:10.1038/nmeth.2603 · Cited by 352
ADP‐ribosyltransferases, an update on function and nomenclature
Lüscher, B., Ahel, I., Altmeyer, M., Ashworth, A., Bai, P., Chang, P., Cohen, M., Corda, D., Dantzer, F., Daugherty, M. D., et al. (2022) · The FEBS Journal · doi:10.1111/febs.16142 · Cited by 305
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I., Bell-McGuinn, K., Coleman, R. L., O'Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 281
Lüscher, B., Bütepage, M., Eckei, L., Krieg, S., Verheugd, P., & Shilton, B. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00122 · Cited by 255
Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Regulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding
Mariotti, L., Pollock, K., & Guettler, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14038 · Cited by 144
Valabrega, G., Scotto, G., Tuninetti, V., Pani, A., & Scaglione, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084203 · Cited by 93
Quantitating drug-target engagement in single cells in vitro and in vivo
Dubach, J. M., Kim, E., Yang, K., Cuccarese, M., Giedt, R. J., Meimetis, L. G., Vinegoni, C., & Weissleder, R. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2248 · Cited by 87
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity
Brady, P. N., Goel, A., & Johnson, M. A. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-18 · Cited by 58
Moreno-Lama, L., Galindo-Campos, M. A., Martínez, C., Comerma, L., Vazquez, I., Vernet-Tomas, M., Ampurdanés, C., Lutfi, N., Martin-Caballero, J., Dantzer, F., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1175-x · Cited by 29
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS
Almeida, G. S., Bawn, C. M., Galler, M., Wilson, I., Thomas, H. D., Kyle, S., Curtin, N. J., Newell, D. R., & Maxwell, R. J. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3736 · Cited by 16
Metadata
- Authors
- Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A.-G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., Kull, B., Robertson, G. M., Pellicciari, R., Schüler, H., & Weigelt, J.
- Venue
- Nature Biotechnology
- Published
- 2012-02-19
- Volume
- 30
- Issue
- 3
- Pages
- 283-288
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2085215116
- Cited by
- 457
- References
- 44
- FWCI
- 22.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.